Increasing the CTC detection sensitivity through FETCH technology

Increasing the CTC detection sensitivity through FETCH technology - FETCH-CTC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53301

Enrollment

Registered

2023-10-02

Start date

2024-05-23

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer - Breast cancer Breast and prostate cancer

Interventions

In the FETCH assay the initial sample preparation is identically to the CellSearch system, using the same dilution buffer and centrifugation steps. Instead of placement into the CellSearch system howe

(9). This specialized array in combination with the close proximity results in a high magnetic force and therefor high sensitivity. The enriched sample is then stained using the same immunofluorescent

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Diagnosed metastatic breast cancer OR metastatic castration resistant prostate cancer A planned blood collection At least 18 years of age

Exclusion criteria

Exclusion criteria: No informed consent

Design outcomes

Primary

Measure	Time frame
The number of CTC found for each of the two methods.	—

Secondary

Measure	Time frame
Number of healthy cells co-captured using the two tested methods.	—

Countries

Netherlands

Contacts

Public ContactM Stevens

University of Twente

m.stevens@utwente.nl0534894101

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)